Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 6/2017

01-11-2017 | Original Article

Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis

Authors: Sikarin Upala, Veeravich Jaruvongvanich, Karn Wijarnpreecha, Anawin Sanguankeo

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2017

Login to get access

Abstract

Several major risk factors for osteoporosis have been identified. One of these risk factors is chronic inflammation. Several recent studies have supported the association between low bone mineral density (BMD) and nonalcoholic fatty liver disease (NAFLD), which comprises a spectrum of disorders involving liver inflammation. However, conflicting evidence regarding this association has been obtained thus far. We, therefore, conducted a meta-analysis of observational studies to show the association between NAFLD and BMD. The Cochrane Central Register of Controlled Trials, Cochrane Library, Medline, and Embase were searched from database inception to November 2014 for all observational studies evaluating the association between NAFLD or nonalcoholic steatohepatitis (NASH) and bone mass, BMD, or osteoporosis. All patients were ≥18 years of age and had no other cause of liver disease, osteoporosis, or pathological bone disease at baseline. Risk factors were NAFLD and NASH; control subjects were individuals without NAFLD. Eleven articles underwent full-length review. Data were extracted from five cross-sectional studies involving 1276 participants; 638 had NAFLD. The main meta-analysis showed no significant difference in BMD between patients with fatty liver disease and controls. Among all variables analyzed, body mass index had the strongest and most significant predictive effect on the difference in BMD. Controversy exists regarding the effect of BMD on NAFLD. Further studies are required to fully show this relationship.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed
2.
go back to reference Sanchez-Riera L, Carnahan E, Vos T, Veerman L, Norman R, Lim SS et al (2014) The global burden attributable to low bone mineral density. Ann Rheum Dis 73:1635–1645CrossRefPubMed Sanchez-Riera L, Carnahan E, Vos T, Veerman L, Norman R, Lim SS et al (2014) The global burden attributable to low bone mineral density. Ann Rheum Dis 73:1635–1645CrossRefPubMed
3.
go back to reference NIH Consensus Development Panel on Osteoporosis Prevention (2001) Diagnosis, and therapy. osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef NIH Consensus Development Panel on Osteoporosis Prevention (2001) Diagnosis, and therapy. osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef
4.
go back to reference Smith BJ, Lerner MR, Bu SY, Lucas EA, Hanas JS, Lightfoot SA et al (2006) Systemic bone loss and induction of coronary vessel disease in a rat model of chronic inflammation. Bone 38:378–386CrossRefPubMed Smith BJ, Lerner MR, Bu SY, Lucas EA, Hanas JS, Lightfoot SA et al (2006) Systemic bone loss and induction of coronary vessel disease in a rat model of chronic inflammation. Bone 38:378–386CrossRefPubMed
5.
go back to reference Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E et al (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthr Rheum 44:1003–1012CrossRef Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E et al (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthr Rheum 44:1003–1012CrossRef
6.
go back to reference Bernstein CN, Leslie WD, Taback SP (2003) Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol 98:1094–1100CrossRefPubMed Bernstein CN, Leslie WD, Taback SP (2003) Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol 98:1094–1100CrossRefPubMed
7.
go back to reference Mann ST, Stracke H, Lange U, Klor HU, Teichmann J (2003) Alterations of bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis. Metabolism 52:579–585CrossRefPubMed Mann ST, Stracke H, Lange U, Klor HU, Teichmann J (2003) Alterations of bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis. Metabolism 52:579–585CrossRefPubMed
8.
go back to reference Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S (2003) Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 30:2365–2368PubMed Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S (2003) Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 30:2365–2368PubMed
9.
10.
go back to reference Moon SS, Lee YS, Kim SW (2012) Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 42:423–429CrossRefPubMed Moon SS, Lee YS, Kim SW (2012) Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 42:423–429CrossRefPubMed
11.
go back to reference Pardee PE, Dunn W, Schwimmer JB (2012) Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther 35:248–254CrossRefPubMed Pardee PE, Dunn W, Schwimmer JB (2012) Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther 35:248–254CrossRefPubMed
12.
go back to reference Purnak T, Beyazit Y, Ozaslan E, Efe C, Hayretci M (2012) The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien Klin Wochenschr 124:526–531CrossRefPubMed Purnak T, Beyazit Y, Ozaslan E, Efe C, Hayretci M (2012) The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien Klin Wochenschr 124:526–531CrossRefPubMed
13.
go back to reference Cui R, Sheng H, Rui XF, Cheng XY, Sheng CJ, Wang JY et al (2013) Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease. Int J Endocrinol 2013:396545CrossRefPubMedPubMedCentral Cui R, Sheng H, Rui XF, Cheng XY, Sheng CJ, Wang JY et al (2013) Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease. Int J Endocrinol 2013:396545CrossRefPubMedPubMedCentral
14.
go back to reference Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL (2005) Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 289:E735–E745CrossRefPubMedPubMedCentral Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL (2005) Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 289:E735–E745CrossRefPubMedPubMedCentral
15.
go back to reference Boonchaya-anant P, Hardy E, Borg BB, Burshell AL (2013) Bone mineral density in patients with nonalcoholic steatohepatitis among end-stage liver disease patients awaiting liver transplantation. Endocr Pract 19:414–419CrossRefPubMed Boonchaya-anant P, Hardy E, Borg BB, Burshell AL (2013) Bone mineral density in patients with nonalcoholic steatohepatitis among end-stage liver disease patients awaiting liver transplantation. Endocr Pract 19:414–419CrossRefPubMed
16.
go back to reference Kaya M, Isik D, Bestas R, Evliyaoglu O, Akpolat V, Buyukbayram H et al (2013) Increased bone mineral density in patients with non-alcoholic steatohepatitis. World J Hepatol 5:627–634CrossRefPubMedPubMedCentral Kaya M, Isik D, Bestas R, Evliyaoglu O, Akpolat V, Buyukbayram H et al (2013) Increased bone mineral density in patients with non-alcoholic steatohepatitis. World J Hepatol 5:627–634CrossRefPubMedPubMedCentral
17.
go back to reference Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283:2008–2012CrossRefPubMed Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283:2008–2012CrossRefPubMed
18.
go back to reference Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed
19.
go back to reference Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046–1055CrossRefPubMed Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046–1055CrossRefPubMed
20.
go back to reference Bhatt SP, Nigam P, Misra A, Guleria R, Qadar Pasha MA (2013) Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India. Atherosclerosis 230:157–163CrossRefPubMed Bhatt SP, Nigam P, Misra A, Guleria R, Qadar Pasha MA (2013) Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India. Atherosclerosis 230:157–163CrossRefPubMed
21.
go back to reference Kim HY, Choe JW, Kim HK, Bae SJ, Kim BJ, Lee SH et al (2010) Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif Tissue Int 86:350–358CrossRefPubMed Kim HY, Choe JW, Kim HK, Bae SJ, Kim BJ, Lee SH et al (2010) Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif Tissue Int 86:350–358CrossRefPubMed
22.
go back to reference Manco M, Marcellini M, Giannone G, Nobili V (2007) Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127:954–960CrossRefPubMed Manco M, Marcellini M, Giannone G, Nobili V (2007) Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127:954–960CrossRefPubMed
23.
go back to reference Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G et al (2007) Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17:517–524CrossRefPubMed Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G et al (2007) Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17:517–524CrossRefPubMed
24.
go back to reference Maimoun L, Sultan C (2011) Effects of physical activity on bone remodeling. Metabolism 60:373–388CrossRefPubMed Maimoun L, Sultan C (2011) Effects of physical activity on bone remodeling. Metabolism 60:373–388CrossRefPubMed
Metadata
Title
Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis
Authors
Sikarin Upala
Veeravich Jaruvongvanich
Karn Wijarnpreecha
Anawin Sanguankeo
Publication date
01-11-2017
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 6/2017
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-016-0807-2

Other articles of this Issue 6/2017

Journal of Bone and Mineral Metabolism 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.